Clinical trials: Obese Subjects
Obesity, Weight Change Trajectory
Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide
Fractyl is evaluating Revita Duodenal Mucosal Resurfacing (DMR) in the REMAIN-1 pivotal study, which is designed to include two cohorts - an open label cohort referred to as REVEAL-1, and a randomized cohort, which includes both…
- Conditions
- Obesity, Weight Change Trajectory, Weight Change, Body
- Trial name
- REMAIN-1 (NCT06484114)
- Testing
- Revita Duodenal Mucosal Resurfacing (DMR)
- Where
- 32 sites in United States
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Fractyl Health Inc.
Obesity
Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033
The purpose of this study is to determine whether fenofibrate effects the toleration, safety, or efficacy biomarkers of CP-742,033, a drug being developed for the treatment of obesity.
- Trial name
- NCT00376285
- Testing
- CP-742,033, Fenofibrate
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Non-alcoholic Fatty Liver Disease (NAFLD)
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease
This short-term, randomized, placebo-controlled, investigator-initiated trial aims to establish metabolic improvements in NAFLD subjects by dietary supplementation with cofactors N-acetylcysteine, L-carnitine tartrate…
- Trial name
- NAFLD (NCT04330326)
- Testing
- Metabolic Cofactor Supplementation, Sorbitol
- Where
- Turkey (Türkiye)
- Volunteers
- 32 people
- Sponsor
- ScandiBio Therapeutics AB
Obese
A Study of Distal Jejunal-release Dextrose in Obese Participants
The primary purpose of the study is to evaluate the efficacy and safety of APHD-012 (distal jejunal-release dextrose [Aphaia technology, AT]) in obese participants.
- Trial name
- NCT05385978
- Testing
- APHD-012, APHD-012P
- Where
- 9 sites in Georgia, Germany and 1 more
- Volunteers
- 150 people
- Sponsor
- Aphaia Pharma US LLC
Overweight and Obesity
A Research Study of How NNC0174-0833 Behaves in Chinese Volunteers Who Are Normal Weight, Overweight or With Obesity
The aim of this study is to look at how the study medicine behaves in participants body and how it is removed from their body. The study compares three different doses of the study medicine in Chinese healthy men.
- Trial name
- NCT05254158
- Testing
- NNC0174 0833
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity
A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects
Following screening, eligible subjects will be enrolled into a 6-week Low Calorie Diet (LCD) lead-in period. Subjects who lose at least 2% of their body weight at the end of the 6-week LCD lead-in period will be randomized to 1…
- Trial name
- NCT01235741
- Testing
- Pramlintide+Metreleptin
- Where
- 18 sites in United States
- Volunteers
- 213 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MK-8521. Part 1 primary hypothesis: Administration of single subcutaneous (SC) doses of MK-8521 is sufficiently safe and well- tolerated…
- Trial name
- NCT02055547
- Testing
- MK-8521 35μg, MK-8521 100μg, MK-8521 125μg
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects
This study represents the second Phase 1 study with GSK376501 and the goal is to further evaluate its safety and tolerability. The way the human body processes GSK376501 will also be determined.
- Trial name
- NCT00495014
- Testing
- GSK376501
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Overweight and Obesity
Efficacy and Safety of Glucosanol™ in Body Weight Reduction
It was proven in a previous clinical study that Glucosanol™ is effective and safe in reducing weight in the overweight and obese.
- Trial name
- NCT02930668
- Testing
- Glucosanol 350mg, Glucosanol 500mg
- Where
- Germany
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Obesity, Overweight
Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects
A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to examine the safety, tolerability, and effect on body weight of subcutaneous AC2307 in obese or overweight subjects.
- Trial name
- NCT00785408
- Testing
- AC2307
- Where
- 18 sites in United States
- Volunteers
- 273 people
- Sponsor
- AstraZeneca
Obesity
A Study to Characterise the Physiology of Weight Loss and Regain Under Dietary, Behavioural and Pharmacological Interventions in Healthy Obese Subjects
Approximately 60 obese, but otherwise healthy, subjects will be assessed in this benchmark study to investigate the physiological changes associated with weight loss and regain.
- Trial name
- NCT01597609
- Testing
- sibutramine
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Obesity; Excess Calories, Overweight and Obesity
Efficacy and Safety of Litramine in 1 Year Weight Loss Study
To evaluate the efficacy of Litramine in reducing body weight in the context of an energy-restricted diet in overweight and moderately obese subjects
- Conditions
- Obesity; Excess Calories, Overweight and Obesity, Weight Loss
- Trial name
- NCT03227276
- Testing
- Litramine
- Where
- Germany
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
This is a multicenter, randomized, open-label Phase 3 clinical study comparing the efficacy and safety of IBI362 9 mg QW versus Semaglutide 2.4 mg QW in overweight or obese (BMI≥27kg/m2) MAFLD subjects.
- Trial name
- NCT06884293
- Testing
- IBI362, semaglutide
- Where
- China
- Volunteers
- 479 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Hypertension
Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients
The purpose of this study is to determine whether BMS-823778 is safe and effective in the treatment of hypertension in overweight and obese patients.
- Trial name
- NCT01602367
- Testing
- BMS-823778
- Where
- 35 sites in United States, Colombia and 3 more
- Volunteers
- 7 people
- Sponsor
- Bristol-Myers Squibb
Healthy Subjects, Obesity
Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes
The phase 1 portion of the study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TLC-6740 after single- and multiple-ascending doses in healthy subjects.
- Conditions
- Healthy Subjects, Obesity, Type 2 Diabetes
- Trial name
- NCT05822544
- Testing
- TLC-6740 Oral Solution, TLC-6740 Tablet, Drug Metabolizing Enzyme
- Where
- 4 sites in New Zealand
- Volunteers
- 564 people, healthy volunteers welcome
- Sponsor
- OrsoBio, Inc
Bstructive Sleep Apnea (OSA) and Obesity
A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity
A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects with Obstructive Sleep Apnea (OSA) and Obesity
- Trial name
- NCT06974851
- Testing
- HRS9531
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Obesity, Overweight
A Study of Tirzepatide in Overweight and Very Overweight Participants
The main purpose of this study is to measure the effect of tirzepatide on food intake in participants who are overweight or very overweight.
- Trial name
- NCT04311411
- Testing
- Tirzepatide, Liraglutide
- Where
- 3 sites in United States
- Volunteers
- 114 people
- Sponsor
- Eli Lilly and Company
Insulin Resistance
Study In Patients With Insulin Resistance
Fluid management study in patients with insulin resistance.
- Trial name
- NCT00197132
- Testing
- Avandia
- Where
- Netherlands
- Volunteers
- 18 people
- Sponsor
- GlaxoSmithKline
Stroke, Hypertension
DELPHI in Subjects at Risk for Stroke and Dementia
The DELPhi system is a software device that is used for the noninvasive evaluation of brain plasticity and connectivity. The DELPhi software uses EEG and TMS devices as accessories.
- Conditions
- Stroke, Hypertension, Diabete Mellitus, Dyslipidemias
- Trial name
- NCT03884647
- Testing
- DELPhI system
- Where
- 4 sites in United States, Israel
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- QuantalX Neuroscience
Prader-Willi Syndrome, Obesity
Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome
The purpose of this study is to evaluate efficacy and safety of ZGN-440 (beloranib) in obese adolescent and adult subjects with Prader-Willi Syndrome.
- Trial name
- bestPWS (NCT02179151)
- Testing
- ZGN-440 for Injectable Suspension
- Where
- 15 sites in United States
- Volunteers
- 108 people
- Sponsor
- Zafgen, Inc.